Letrozole
High-grade Serous Ovarian Cancer (HGSOC)
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the High-grade Serous Ovarian Cancer (HGSOC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Abemaciclib AstraZeneca | Phase 2 | B |
Palbociclib National Cancer Institute (NCI) | Phase 2 | B |
FULVESTRANT University of Oklahoma | Phase 2 | B |
Aitua Combination Antibody Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | CCC |
azd8421 AstraZeneca | Phase 1/2 | CC |
View all 9 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →